On November 6, 2017
, the FDA approved alectinib (Alecensa; Genentech) for the treatment of patients with ALK
mutation–positive, metastatic non–small-cell lung cancer (NSCLC), as detected by an FDA-approved test. On the same day, the FDA also converted alectinib’s initial accelerated approval to a full approval for the treatment of patients with metastatic NSCLC and ALK
mutation whose disease progressed with or who were intolerant of crizotinib (Xalkori).
[ Read More ]